Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis to acquire US BiPar Sciences

Sanofi-aventis has announced it has agreed to purchase US biopharmaceutical company, BiPar Sciences

Sanofi-aventis has announced it has agreed to purchase US biopharmaceutical company, BiPar Sciences.

California-based BiPar specialises in the development of pioneering treatments for several different cancers through DNA repair using PARP (Poly ADP-Ribose Polymerase) inhibitors. BSI-201 enhances the effects of chemotherapy by preventing cancer cells from repairing their own DNA and therefore leading to the death of cancer cells.

BiPar's lead product candidate, BSI-201, is currently undergoing Phase 2 trials for the treatment of metastatic triple negative breast cancer and ovarian cancer among others.

Christopher A Viehbacher, CEO of sanofi-aventis said: "This acquisition illustrates our strong commitment to oncology to provide patients, physicians and public health stakeholders with breakthrough medicines addressing unmet medical needs".

Under the terms of the agreement, the final price of the deal depends on BSI-201 achieving milestone payments. The price could reach a maximum of $500m.

15th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics